Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLPG3970 in Active Systemic Lupus Erythematosus
NCT04700267Phase 1Terminated
- Sponsor
- Galapagos NV
- Start
- Dec 2020
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing GLPG3970 with Placebo (2 arms). Primary endpoints: Change in biomarkers associated with disease anti-dsDNA at Day 104, Change in biomarkers associated with disease complement component 3 at Day 104 and 2 more. Started Dec 2020; status: terminated.
02
Drugs
GLPG3970
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT04700267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04700267.